Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00287833 · ClinicalTrials.gov registry record · Phase 1
Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Healthy Men
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00287833: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00287833 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00287833, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This randomized phase I trial is studying the side effects and best dose of Bowman-Birk inhibitor concentrate in preventing cancer in healthy men. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of Bowman-Birk inhibitor concentrate may prevent cancer.
Interventions
- OTHER placebo
- DRUG Bowman-Birk inhibitor concentrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00287833
The ClinicalTrials.gov registry entry for NCT00287833 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00287833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00287833 about?
NCT00287833 is a clinical study titled "Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Healthy Men". This randomized phase I trial is studying the side effects and best dose of Bowman-Birk inhibitor concentrate in preventing cancer in healthy men. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of Bowman-Birk inhibitor concentrate may preven...
What is the current status of trial NCT00287833?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2006-01.
What interventions are being tested in trial NCT00287833?
The interventions under investigation include: placebo (OTHER), Bowman-Birk inhibitor concentrate (DRUG).
Who is sponsoring clinical trial NCT00287833?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.